INOVIO PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.42 USD | +0.53% |
|
+2.42% | +86.60% |
| May. 14 | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
| May. 13 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 330 | 1,499 | 1,050 | 389.2 | 139.2 | 295.9 | - | - |
| Enterprise Value (EV) 1 | 330 | 1,499 | 1,050 | 389.2 | 139.2 | 295.9 | 295.9 | 295.9 |
| P/E ratio | -2.73 x | -8.27 x | -3.44 x | -1.33 x | -1 x | -2.66 x | -3.41 x | -8.62 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 80.3 x | 202 x | 592 x | 37.9 x | 167 x | 617 x | 33.5 x | 3.78 x |
| EV / Revenue | 80.3 x | 202 x | 592 x | 37.9 x | 167 x | 617 x | 33.5 x | 3.78 x |
| EV / EBITDA | - | - | -3,526,960 x | -1,477,500 x | - | - | - | - |
| EV / FCF | - | - | -4.84 x | -1.79 x | -1.12 x | -3.4 x | -3.89 x | -5.19 x |
| FCF Yield | - | - | -20.7% | -55.8% | -89.6% | -29.4% | -25.7% | -19.3% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 8,334 | 14,117 | 17,532 | 20,791 | 22,749 | 25,907 | - | - |
| Reference price 2 | 39.60 | 106.2 | 59.88 | 18.72 | 6.120 | 11.42 | 11.42 | 11.42 |
| Announcement Date | 3/12/20 | 3/1/21 | 3/1/22 | 3/1/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.112 | 7.411 | 1.775 | 10.26 | 0.832 | 0.4797 | 8.823 | 78.19 |
| EBITDA | - | - | -297.7 | -263.4 | - | - | - | - |
| EBIT 1 | -111.1 | -124.1 | -301.2 | -267.6 | -143.9 | -123.3 | -100.5 | -54.41 |
| Operating Margin | -2,702.1% | -1,674.25% | -16,972.32% | -2,607.35% | -17,300.28% | -25,703.92% | -1,138.58% | -69.59% |
| Earnings before Tax (EBT) 1 | -120.8 | -162.9 | -303.2 | -277.7 | -135.1 | -116.3 | -109.8 | -53.22 |
| Net income 1 | -119.4 | -166.4 | -303.7 | -279.8 | -135.1 | -118.2 | -109.4 | -79.56 |
| Net margin | -2,902.75% | -2,245.39% | -17,109.85% | -2,726.67% | -16,239.87% | -24,639.91% | -1,240.18% | -101.75% |
| EPS 2 | -14.52 | -12.84 | -17.40 | -14.04 | -6.090 | -4.286 | -3.348 | -1.325 |
| Free Cash Flow 1 | - | - | -216.9 | -217.2 | -124.7 | -87 | -76 | -57 |
| FCF margin | - | - | -12,223.6% | -2,116.34% | -14,986.17% | -18,137.47% | -861.35% | -72.9% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/1/21 | 3/1/22 | 3/1/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.8391 | 0.1991 | 0.7844 | 9.154 | 0.1247 | 0.1149 | 0.226 | 0.3884 | 0.1026 | - | 0.1572 | 0.1575 | 0.1702 | 0.1 | 0.1 |
| EBITDA | -104.4 | - | -103.1 | -34.73 | -54.95 | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -105.5 | -71.73 | -104.1 | -35.76 | -55.95 | -43.95 | -37.04 | -35.55 | -27.39 | -31.48 | -31.61 | -32.19 | -32.56 | - | - |
| Operating Margin | -12,573.69% | -36,034.06% | -13,276.05% | -390.61% | -44,875.4% | -38,239.24% | -16,392.04% | -9,152.53% | -26,686.55% | - | -20,103.97% | -20,438.41% | -19,122.61% | - | - |
| Earnings before Tax (EBT) 1 | -106.9 | -79.07 | -108.5 | -37.78 | -54.46 | -40.65 | -35.53 | -33.93 | -25 | -30.47 | -30.91 | -31.54 | -32.27 | - | - |
| Net income 1 | -106.9 | -79.07 | -108.5 | -37.78 | -54.46 | -40.65 | -35.53 | -33.93 | -25 | -30.47 | -29.04 | -29.52 | -28.32 | - | - |
| Net margin | -12,745.21% | -39,721.57% | -13,831.89% | -412.75% | -43,685.84% | -35,365.69% | -15,725.33% | -8,734.68% | -24,358.15% | - | -18,464.39% | -18,744.76% | -16,632.76% | - | - |
| EPS 2 | -6.000 | -4.320 | -5.520 | -1.800 | -2.640 | -1.920 | -1.560 | -1.560 | -5.670 | -1.310 | -1.076 | -1.052 | -0.9380 | -1.160 | -1.070 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/1/22 | 5/10/22 | 8/9/22 | 11/8/22 | 3/1/23 | 5/10/23 | 8/9/23 | 11/9/23 | 3/6/24 | 5/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -217 | -217 | -125 | -87 | -76 | -57 |
| ROE (net income / shareholders' equity) | - | - | -70.6% | -90% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | -12.40 | -10.90 | - | - | - | - |
| Capex | - | - | 1.23 | - | - | - | - | - |
| Capex / Sales | - | - | 69.36% | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/1/21 | 3/1/22 | 3/1/23 | 3/6/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
11.42
USD
Average target price
19.4
USD
Spread / Average Target
+69.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +86.60% | 296M | |
| +29.03% | 49.18B | |
| -0.10% | 42.11B | |
| +47.02% | 40.37B | |
| -5.26% | 28.85B | |
| +11.48% | 26.09B | |
| -22.74% | 18.71B | |
| +9.06% | 13.26B | |
| +30.01% | 12.32B | |
| -1.51% | 11.99B |
- Stock Market
- Equities
- INO Stock
- Financials Inovio Pharmaceuticals, Inc.